Article
Oncology
Sebastian Bauer, Robin L. Jones, Jean-Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schoeffski, Margaret von Mehren, John R. Zalcberg, Yoon-Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Meade, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz-Soto, Michael C. Heinrich
Summary: This study compared the efficacy and safety of ripretinib and sunitinib in patients with advanced GIST previously treated with imatinib. The results showed that ripretinib was not superior to sunitinib in terms of progression-free survival (PFS), but it had fewer treatment-emergent adverse events and better tolerability.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
C. Roecken
Summary: This review summarizes the advancements in tissue-based diagnostic biomarkers for gastric cancer, including different types of gastric cancer and their associated molecular changes. The importance of adequate tissue sampling and the risk of sampling error in gastric cancer biomarker research are also highlighted.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Engineering, Biomedical
Francisca Diniz, Sofia Lamas, Hugo Osorio, Paulo Aguiar, Daniela Freitas, Fatima Gartner, Bruno Sarmento, Celso A. Reis, Joana Gomes
Summary: This study demonstrates the potential of using nanoparticles targeting STn for delivering FRT as a therapeutic approach in gastric cancer. The nanoparticles effectively reduced tumor growth, cell proliferation, and tumor necrosis in vivo.
ACTA BIOMATERIALIA
(2023)
Article
Biochemistry & Molecular Biology
Robin Frobom, Erik Berglund, Craig A. Aspinwall, Weng-Onn Lui, Inga-Lena Nilsson, Catharina Larsson, Robert Branstrom
Summary: The study investigated the effects of three clinically established TKIs (imatinib, sunitinib, nilotinib) on KATP channel activity, revealing that these drugs can decrease KATP channel activity by interacting with the ATP-binding site on the channel. This interaction may contribute to some of the side effects associated with TKIs.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Review
Oncology
Rossella Elisei, Enrique Grande, Michael C. Kreissl, Sophie Leboulleux, Tarun Puri, Nicolas Fasnacht, Jaume Capdevila
Summary: The incidence of thyroid cancer is increasing globally, with Europe ranking second in disease burden after Asia. Over the past few decades, research has identified key molecular pathways and targetable kinases/drivers for each histologic subtype of thyroid cancer. Newer and selective RET inhibitors, such as selpercatinib and pralsetinib, have shown promising efficacy and favorable toxicity profiles in clinical trials for the treatment of RET-driven advanced thyroid cancer. Genetic testing is crucial to identify RET alterations and determine the optimal treatment approach.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Bibian M. E. Tullemans, Delia Fernandez, Alicia Veninga, Constance C. F. M. J. Baaten, Linsey J. F. Peters, Maureen J. B. Aarts, Johannes A. Eble, Elena Campello, Luca Spiezia, Paolo Simioni, Emiel P. C. van der Vorst, Paola E. J. van der Meijden, Johan W. M. Heemskerk, Marijke J. E. Kuijpers
Summary: Sunitinib inhibits collagen-induced procoagulant activity and delays fibrin formation, which is exacerbated by aspirin. Therefore, we urge awareness of the combined antiplatelet effects of TKIs with aspirin, as this may lead to an increased risk of bleeding.
THROMBOSIS AND HAEMOSTASIS
(2022)
Review
Oncology
Emaan Haque, Abdullah Esmail, Ibrahim Muhsen, Haneen Salah, Maen Abdelrahim
Summary: Gastric cancer is the fifth most common tumor worldwide. Recent advancements have been made in the diagnosis and treatment of the disease, including improvements in non-invasive diagnostic techniques and the identification of new therapeutic targets. A multidisciplinary approach and cytotoxic chemotherapy are the main treatment options currently available.
Review
Oncology
Jiabao Hou, Hongle Li, Shuxiang Ma, Zhen He, Sen Yang, Lidan Hao, Hanqiong Zhou, Zhe Zhang, Jing Han, Li Wang, Qiming Wang
Summary: Platinum-based chemotherapy used to be the first choice for lung cancer, but EGFR tyrosine kinase inhibitors (TKIs) have become preferred treatment for NSCLC patients with EGFR gene mutations. However, patients with EGFR exon 20 insertion (ex20ins) mutations have poor prognosis and are insensitive to EGFR-TKIs. Recent clinical research has focused on developing therapies specifically targeting ex20ins mutations.
BIOMARKER RESEARCH
(2022)
Review
Chemistry, Analytical
Asmaa M. AboulMagd, Nada S. Abdelwahab
Summary: This review discusses the characteristics and analytical methods for determination of sunitinib malate, emphasizing the need for alternative methods that are cost-effective, require minimal sample preparation, consume less toxic solvents, and leave minimal residue. The literature also reveals a lack of research on potential drug-drug pharmacokinetic interactions.
MICROCHEMICAL JOURNAL
(2021)
Article
Pharmacology & Pharmacy
Caiyun Nie, Weifeng Xu, Huifang Lv, Xiaohui Gao, Guofeng Li, Beibei Chen, Jianzheng Wang, Yingjun Liu, Jing Zhao, Yunduan He, Saiqi Wang, Xiaobing Chen
Summary: This study evaluated the clinical efficacy and safety of different treatment strategies for patients with advanced or metastatic gastric cancer. The results showed that anti-angiogenic TKIs plus chemotherapy demonstrated superior therapeutic efficacy compared to chemotherapy alone, while TKIs + ICIs did not show a clinical advantage over chemotherapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Wentao Liu, Dianyun Ren, Wei Xiong, Xin Jin, Liang Zhu
Summary: Our study identified that NFAT1, when overexpressed in RCC, was associated with poor prognosis and could enhance tumor growth by increasing PD-L1 expression. Additionally, NFAT1 was found to be stabilized in sunitinib-resistant RCC through hyperactivation of the PI3K/AKT/GSK-3 beta signaling pathway. The downregulation of FBW7, which promotes NFAT1 degradation, was induced by FOXA1 and SETD2 in sunitinib-resistant RCC, contributing to immune response modulation. This study reveals a new role for the FBW7/NFAT1 axis in RCC response to TKIs and ICIs, suggesting NFAT1 as a potential therapeutic target for RCC treatment.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Zhengqi Wen, Dun Xiong, Shurong Zhang, Jiankun Liu, Bitao Li, Raomei Li, Hushan Zhang
Summary: Gastric cancer treatment options are limited due to insufficient understanding of molecular characteristics. A novel form of ALK fusion was identified in gastric cancer.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Donghan Xu, Yehao Luo, Peng Wang, Jiaxin Li, Linrui Ma, Jie Huang, Hao Zhang, Xiaoman Yang, Liqi Li, Yuhong Zheng, Gang Fang, Peiyu Yan
Summary: The incidence of gastric cancer is increasing and current treatment options are not satisfactory due to most cases being diagnosed at an advanced stage. Anti-angiogenesis targeted therapies have shown potential for gastric cancer treatment. In this review, the efficacy and safety of various targeted drugs were evaluated, and response biomarkers were identified. The challenges and available solutions for anti-angiogenesis therapy in gastric cancer were also discussed. This review provides valuable references for future clinical research in this field.
FRONTIERS IN ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Viktoria F. Koehler, Pia Adam, Karin Frank-Raue, Friedhelm Raue, Elke Berg, Eva Hoster, Stephanie Allelein, Matthias Schott, Matthias Kroiss, Christine Spitzweg
Summary: The study evaluated the efficacy of vandetanib and cabozantinib in treating patients with medullary thyroid cancer outside of clinical trials at four German tertiary care centers. The findings suggest that both drugs are effective treatment options for the majority of patients with MTC.
Article
Medicine, General & Internal
Zhusheng Zhang, Qiyuan Bao, Yucheng Fu, Junxiang Wen, Meng Li, Zhuochao Liu, Guoyu He, Beichen Wang, Yuhui Shen, Weibin Zhang
Summary: The feasibility of drug discontinuation for sarcoma patients with a very favorable response to antiangiogenic TKIs remains unknown. This study explores the outcomes of advanced sarcoma patients who discontinued AA-TKIs after achieving a (near-) complete remission or long-term response. Results show that most patients were still sensitive to the original AA-TKIs and achieved a second remission after disease progression. Surgical remission, blood biomarkers, and tumor necrosis rates were potential predictors for AA-TKI withdrawal.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Hematology
Marie-Kristin Schwaegermann, Lukas Hobohm, Johanna Rausch, Michael Reuter, Thomas-Friedrich Griemert, Visvakanth Sivanathan, Tanja Falter, Martin F. Sprinzl, Karl J. Lackner, Peter R. Galle, Stavros Konstantinides, Matthias Theobald, Charis von Auer
Summary: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare autoimmune disorder characterized by reduced activity of ADAMTS13 due to autoantibodies. This results in thrombotic microangiopathy, decreased platelet count, hemolysis, and tissue ischemia.
Letter
Gastroenterology & Hepatology
Christian Labenz, Frank Lammert, Peter R. Galle
JOURNAL OF HEPATOLOGY
(2023)
Article
Health Care Sciences & Services
Maurice Michel, Alisha Wahl, Malena Anders, Saleh A. Alqahtani, Wolfgang M. Kremer, Peter R. Galle, Christian Labenz, Daniel Grimm, Martin Sprinzl, Joern M. Schattenberg
Summary: Metabolic comorbidities, significant fibrosis, and a lower socioeconomic status may negatively affect the health-related quality of life in people living with human immunodeficiency virus (HIV).
QUALITY OF LIFE RESEARCH
(2023)
Article
Oncology
Chiun Hsu, Michel Ducreux, Andrew X. Zhu, Shukui Qin, Masafumi Ikeda, Tae-You Kim, Peter R. Galle, Richard S. Finn, Ethan Chen, Ning Ma, Youyou Hu, Lindong Li, Ann-Lii Cheng
Summary: The IMbrave150 trial showed that atezolizumab + bevacizumab is safe and effective in treating patients with hepatocellular carcinoma, including those with hepatitis B or hepatitis C infection.
Article
Gastroenterology & Hepatology
Sophia Heinrich, Thomas Austgen, Darko Castven, Moritz Hess, Christian Labenz, Martha Kirstein, Carolin Zimpel, Lena Stockhoff, Benjamin Maasoumy, Bernd Heinrich, Hans Heinrich Wedemeyer, Peter Robert Galle, Harald Binder, Marc Nguyen-Tat, Jens Uwe Marquardt
Summary: In this study, serum levels of M30 and M65 were found to be able to effectively distinguish responders from non-responders to terlipressin therapy in patients with hepatorenal syndrome (HRS), and predict dialysis- and liver transplantation (LTX)-free survival.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Oncology
Jens Mittler, Stefan Heinrich, Martina Koch, Maria Hoppe-Lotichius, Ali Hadian, Arndt Weinmann, Roman Kloeckner, Peter Robert. Galle, Hauke Lang
Summary: In a study of nearly 100 elderly patients undergoing LT for cirrhosis-associated hepatocellular carcinoma, it was found that patients aged 65 and older can benefit from LT, with outcomes comparable to younger patients.
Article
Oncology
Masatoshi Kudo, Richard S. S. Finn, Peter R. R. Galle, Andrew X. X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni
Summary: The study demonstrates the efficacy and safety of atezolizumab + bevacizumab treatment in patients with baseline BCLC Stage B hepatocellular carcinoma, consistent with the overall study population.
Article
Oncology
Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel
Summary: This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab + bevacizumab or sorafenib. The study found that atezolizumab + bevacizumab improved overall survival and progression-free survival compared to sorafenib in patients with ALBI score of 1, but not in patients with ALBI score of 2. ALBI grade appeared to be prognostic for outcomes in both treatment groups.
Review
Gastroenterology & Hepatology
Simon J. Gairing, Eva M. Schleicher, Peter R. Galle, Christian Labenz
Summary: Hepatic encephalopathy is a significant complication of liver cirrhosis with detrimental effects on patients' quality of life. Identifying high-risk patients and implementing early prevention is crucial. Cognitive tests, composite scores, and blood-based biomarkers have shown promise in predicting the first-time occurrence of hepatic encephalopathy. However, the evidence for primary prophylaxis is limited.
HEPATOLOGY COMMUNICATIONS
(2023)
Article
Cardiac & Cardiovascular Systems
Omar Hahad, Donya A. Gilan, Julian Chalabi, Sadeer Al-Kindi, Alexander K. Schuster, Felix Wicke, Matthias Buettner, Oliver Tuescher, Karl J. Lackner, Peter R. Galle, Stavros Konstantinides, Andreas Daiber, Philipp S. Wild, Thomas Muenzel
Summary: This study aims to investigate the association between social disadvantage and cardiovascular burden and mortality. The findings suggest that low socioeconomic status is associated with increased risk of cardiovascular disease and mortality, with education and occupation being stronger predictors compared to household net income.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Tiemo Sven Gerber, Hagen Roland Witzel, Arndt Weinmann, Fabian Bartsch, Mario Schindeldecker, Peter R. Galle, Hauke Lang, Wilfried Roth, Dirk Andreas Ridder, Beate Katharina Straub
Summary: This study investigated the levels of 4-hydroxy-nonenal (4-HNE) in liver carcinomas and analyzed their correlation with clinical data and survival outcomes. The results showed that lower levels of 4-HNE were associated with unfavorable survival outcomes and aggressive tumor behavior in hepatocellular carcinoma (HCC). However, in intrahepatic cholangiocarcinoma (iCCA), 4-HNE levels were not correlated with prognostic parameters or survival outcomes.
Article
Gastroenterology & Hepatology
Natascha Roehlen, Fabian Stoehr, Lukas Mueller, Hendrik Luxenburger, Simon J. Gairing, Marlene Reincke, Michael Schultheiss, Floriona Berisha, Arndt Weinmann, Friedrich Foerster, Jens U. Marquardt, Robert Thimme, Peter R. Galle, Dominik Bettinger, Roman Kloeckner
Summary: This study demonstrates that tumor size and absence of liver cirrhosis are predictors of severe postembolization syndrome (PES) in HCC patients after TACE and are associated with poor prognosis.
HEPATOLOGY COMMUNICATIONS
(2023)
Letter
Gastroenterology & Hepatology
Simon Johannes Gairing, Leonard Kaps, Eva Maria Schleicher, Peter Robert Galle, Christian Labenz
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Oncology
M. Moehler, C. Zimpel, S. Warnke, F. Forster, A. Weinmann, K. Schulze, H. Wege, J. Von Felden, D. Waldschmidt, P. R. Galle, C. Ruckes, J. U. Marquardt
ONCOLOGY RESEARCH AND TREATMENT
(2022)
Meeting Abstract
Medicine, General & Internal
Simon Johannes Gairing, Julian Anders, Leonard Kaps, Michael Nagel, Maurice Michel, Wolfgang Maximilian Kremer, Max Hilscher, Peter Robert Galle, Joern M. Schattenberg, Marcus-Alexander Woerns, Christian Labenz
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)